Our viral vaccine capabilitiess include generation, production, purification and analysis of DNA and RNA viruses manufactured on mammalian cell lines.
Our contribution to Global Health
In pursuit of increasing global vaccination coverage, we are committed to develop technologies that substantially lower the cost of vaccine manufacturing. Hereto, we develop highly intensified production process for viral vaccines, HIP-Vax, to reduce cost of product by decreasing CAPEX and cost of goods. Furthermore, we have developed SCOUT® technology to reduce development timelines and time to market. As it is known that costs of capital (53%) and cost of failure (40%) are the biggest cost attributes to a vaccine price paid by consumers, our platforms substantially aid global health initiatives to reach their goals.
Viral vaccines track record
We have extensive experience in manufacturing a wide range of viruses including polio, measles, rubella, influenza and rotavirus. We are proud to have delivered vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering vaccine products. For example, in a collaboration with PATH, we have manufactured GMP virus stocks of several novel oral polio vaccine strains. In addition, in collaboration with Prof. Marcellus Ubbink (Leiden University, Netherlands) we are developing a very promising new class of vaccines: self-adjuvating, thermostable influenza vaccines.
Viral vaccines technologies
HIP-Vax technology®
Under the HIP-Vax® brand, we market our process development services and know-how which enables fast and low-cost vaccine manufacturing using bioprocess intensification technologies.
SATIRN® technology
The SATIRN® technology delivers a platform to manufacture potent, self-adjuvating, thermostable, membrane protein-based vaccines.
SCOUT® technology
The SCOUT® technology provides for an effective tool for “Design-of-Experiments” (DoE) approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.
Process development
We develop scalable, robust and GMP-compliant manufacturing processes for viral vaccines.
Upstream process development
We deliver scalable and robust GMP-compliant processes for viral vaccines.
Downstream process development
We deliver scalable and robust GMP-compliant processes for viral vaccines.
Analytical development
We perform and develop all the required product-specific release and stability assays for your viral vaccine.
In silico cost modeling
We often perform in silico cost modeling of manufacturing processes for viral vaccines.
Related resources
You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in…
Written by expert: Marije, GMP Scientist Many customers want to know how much time it will take to move a candidate viral vaccine or viral vector product from bench to…
Written by expert: Ahd, Director Project Management Current costs of biopharmaceutical manufacturing often prevent segments of the world’s population from accessing critical medicines. Sometimes the costs even prevent medicines from…
Written by expert: Monika, Associate Director Viral Vector Development Despite having very limited coding capacity, most of the RNA viruses are surprisingly good at escaping the hosts immune response and withstanding…
Talk to our experts
